progression-free survival
Background: Osimertinib is third-generation TKI drug, The FLAURA study results have demonstrated the effectiveness of Osimertinib as a first-line treatment, showing an improvement in progression-free survival (PFS) of up to 18.9 months and overall survival (OS) of 38.6 months.
Background : Osimertinib is third-generation TKI drug, The FLAURA study results have demonstrated the effectiveness of Osimertinib as a first-line treatment, showing an improvement in progression-free survival ( PFS ) of up to 18 .9 months and overall survival ( OS ) of 38 .6 months .